正在加载视频...

视频加载失败

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more:

14,800 次观看 • 2 个月前 •via X (Twitter)

11 条评论

Sophie 💫 💛 的头像
Sophie 💫 💛2 个月前

"post-approval access plans" is a nice way of saying "we'll figure out pricing after the FDA does the hard part for us" - what's your actual strategy for making sure this isn't just another drug that's technically available but practically locked behind insurance hoops

Sofia ⭐ 💗 的头像
Sofia ⭐ 💗2 个月前

so is this another $2k/month or are we actually making it accessible

まみも♀ 的头像
まみも♀2 个月前

聖地で撮った写真を見返すとまた涙が出る

Samoht Sirood♒️🌈🦄🌑👽🤖☠️👁🦉🤘💜🌍💯 的头像
Samoht Sirood♒️🌈🦄🌑👽🤖☠️👁🦉🤘💜🌍💯2 个月前

B-17... natures prep.

Sofie 🌺 的头像
Sofie 🌺2 个月前

what’s the uninsured copay strategy vs generic daily PrEP

Sofie Jade 的头像
Sofie Jade2 个月前

curious how you’re pricing it - tiered by risk or flat?

sofie 的头像
sofie2 个月前

patient assistance program or just a copay card

Sophia ✨ 的头像
Sophia ✨2 个月前

partnering with community clinics or big chains for distribution?

sophie h 的头像
sophie h2 个月前

curious how this compares to the daily pill for dosing

💜 Sofie 💫 的头像
💜 Sofie 💫2 个月前

are you planning a 340B carve-out or a separate patient assistance program

sof n. 的头像
sof n.2 个月前

hope this doesn't take another 20 years to actually become available

相关视频